Identification
Instrument name
ADVICENNE
Symbol
ADVIC
ISIN code
FR0013296746
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Website address
Operation
IPO date
IPO type
Dual listing
Catégorie
IPO

Company profile

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2018, the group had 2 products in clinical development phase, including ADV7103 in Phase III for the treatment of distal renal tubular acidosis and in Phase II/III for the treatment of cystinuria, and ADV6770 in Phase I for the treatment of absence epilepsy.

Source: Cofisem - Last Update: 02 Sep 2020
Key Executives
CEO Ad Interim André Ulmann
Deputy CEO Nathalie Lemarié
Administrative & Finance Director Paul Michalet
Investor Relations Director Julie Rachline
Source: Cofisem - Last Update: 05 Jun 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 1,999 963 557 268 109
Income from ordinary activities 4,210 6,813 2,568 1,815 604
Operating income -14,626 -5,292 -5,974 -3,168 -3,447
Cost of financial indebtedness net 46 8 -69 -405 -164
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -13,714 -5,015 -6,048 -3,574 -3,609
Net income (Group share) -13,714 -5,015 -6,048 -3,574 -3,609
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 02 Sep 2020
Shareholder information
Bpifrance Investissement 26.73 %
Free float 17.90 %
IXO Private Equity 17.38 %
Cemag Invest 9.10 %
Marie-Odile Humblet 7.10 %
Irdi Soridec Gestion 5.18 %
Jean-Pierre Lefoulon 4.41 %
Françoise Brunner-Ferber 3.98 %
Luc-André Granier 3.77 %
Caroline Roussel-Maupetit 2.49 %
Employees 1.19 %
Ludovic Robin 0.35 %
Group-owned stock 0.26 %
Nathalie Lemarié 0.16 %
Source: Cofisem - Last Update: 05 Jun 2020